GlaxoSmithKline (GSK) has launched Shingrix, a recombinant zoster vaccine, in Malaysia to prevent shingles and post-herpetic neuralgia in adults aged 50 and over. The vaccine has shown up to 97% efficacy in clinical trials and is aimed at reducing the significant health burden of shingles. In related news, GSK has presented data from a phase 3 trial demonstrating that co-administering its RSV vaccine Arexvy with Shingrix produces an equivalent immune response compared to administering them separately, potentially simplifying the vaccination process for older adults. This co-administration strategy aligns with GSK's efforts to enhance adult immunization rates and could support regulatory submissions globally. Despite some recent sales challenges, GSK continues to prioritize vaccines to offset declining revenues from older medications. The combined vaccine approach aims to address the public health impact of both RSV and shingles, which affect millions of older adults annually.